Sign In
Buy LLY
$1,169.86
+53.75 (+4.82%)
At Close: Aug 05, 2026
This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy?
09:00am, Friday, 19'th Sep 2025
Recent breakthroughs in artificial intelligence (AI) are producing tangible results, and not just in the tech industry, although companies in that sector tend to dominate the AI headlines. Even in hea
Where Will Eli Lilly Be in 3 Years?
08:15am, Friday, 19'th Sep 2025
Even with the pullback it has experienced this year, Eli Lilly (LLY 0.37%) has crushed the market over the past three years. The company's shares have more than doubled over this period, making it one
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
12:21pm, Thursday, 18'th Sep 2025
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today
12:05pm, Thursday, 18'th Sep 2025
Two of the hottest healthcare stocks in recent years have been Novo Nordisk (NVO 6.10%) and Eli Lilly (LLY 0.46%). The former has risen by 400% in the past five years, while the latter is up 67%.
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
11:51am, Thursday, 18'th Sep 2025
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
08:57am, Thursday, 18'th Sep 2025
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
3 Dividend Growth Stocks You Can Buy and Forget About
04:50am, Thursday, 18'th Sep 2025
If you want a good dividend growth stock to buy and not worry about, look no further. The three stocks that I've listed here have tremendous long-term growth prospects, offer great dividends, and have
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
06:04pm, Wednesday, 17'th Sep 2025
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting
Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms
02:25pm, Wednesday, 17'th Sep 2025
Eli Lilly and Company's hot streak of obesity and type 2 diabetes readouts ended in early August when we saw underwhelming top-line phase 3 results of orforglipron in obesity patients. Orforglipron lo
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
12:26pm, Wednesday, 17'th Sep 2025
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
3 Stocks Insiders Are Buying Non-Stop
10:28am, Wednesday, 17'th Sep 2025
Insider buying is one of the few market signals that does not hide behind algorithms or price targets.
Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival
10:17am, Wednesday, 17'th Sep 2025
The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk's oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
09:00am, Wednesday, 17'th Sep 2025
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill,
Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
05:39am, Wednesday, 17'th Sep 2025
Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its U.S. dominance globally, the company's international president t
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill
03:43am, Wednesday, 17'th Sep 2025
Eli Lilly's international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration's new fast-track review process, cautioning it was too earl
